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Abstract
Introduction
Bipolar disorder (BD) is a chronic psychiatric disease which can take most different and
unpredictable courses. It is accompanied by unspecific brainstructural changes and cogni-
tive decline. The neurobiological underpinnings of these processes are still unclear. Emerg-
ing evidence suggests that tryptophan catabolites (TRYCATs), which involve all metabolites
of tryptophan towards the kynurenine (KYN) branch, are involved in the etiology as well as
in the course of BD. They are proposed to be mediators of immune-inflammation and neuro-
degeneration. In this study we measured the levels of KYN and its main catabolites consist-
ing of the neurotoxic hydroxykynurenine (3-HK), the more neuroprotective kynurenic acid
(KYNA) and anthranilic acid (AA) and evaluated the ratios between end-products and sub-
strates as proxies for the specific enzymatic activity (3-HK/KYN, KYNA/KYN, AA/KYN) as
well as 3-HK/KYNA as a proxy for neurotoxic vs. neuroprotective end-product relation in
individuals with BD compared to healthy controls (HC).
Methods
We took peripheral TRYCAT blood levels of 143 euthymic to mild depressive BD patients
and 101 HC. For statistical analyses MANCOVA’s controlled for age, sex, body mass index,
cardiovascular disease and smoking were performed.
Results
The levels of KYNA (F = 5,579; p <.05) were reduced in BD compared to HC. The enzymatic
activity of the kynurenine-3-monooxygenase (KMO) reflected by the 3-HK/KYN ratio was
increased in BD individuals compared to HC (F = 5,394; p <.05). Additionally the ratio of 3-
HK/KYNA was increased in individuals with BD compared to healthy controls (F = 11,357;
p <.01).
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Discussion
In conclusion our findings subserve the concept of KYN -pathway alterations in the patho-
physiology of BD. We present evidence of increased breakdown towards the neurotoxic
branch in KYN metabolism even in a euthymic to mild depressive state in BD. From litera-
ture we know that depression and mania are accompanied by inflammatory states which
should be capable to produce an even greater imbalance due to activation of key enzymes
in the neurotoxic direction of KYN -conversion. These processes could finally be involved in
the development of unspecific brain structural changes and cognitive deficits which are
prevalent in BD. Further research should focus on state dependent changes in TRYCATs
and its relation to cognition, brain structure and staging parameters.
Introduction
Bipolar disorder (BD) is a chronic psychiatric disease which can take most different and
unpredictable courses. It is accompanied by unspecific brain structural changes and cognitive
decline [1–6]. In the absence of reliable biomarkers, the diagnosis and evaluation of treatment
success in BD is solely based upon clinical phenomenology and individual interpretation.
Thus, the neurobiological underpinnings of BD are of particular interest and under permanent
investigation.
Emerging evidence suggests that immune-inflammatory activity and tryptophan catabolites
(TRYCATs) changes are involved in the etiology as well as in the course of BD. TRYCATs are
proposed to be mediators of immune-inflammatory activity and also neurodegeneration [7].
Depression and mania are accompanied by the activation of immune inflammatory pathways
like increased levels of pro-inflammatory cytokines which are connected to alterations in the
TRYCAT metabolism [8].
Tryptophan is an essential amino acid and precursor for two critical biochemical pathways
relevant to the inflammatory neuropsychiatric interface involving the generation of neuro-
transmitter 5- hydroxytryptamine (5-HT, serotonin) and the formation of kynurenine (KYN)
and its derivatives [9].
First interpretations of these pathways involved that pro-inflammatory conditions lead to
an induction of indoleamine 2,3-dioxygenase-1 (IDO-1) under which tryptophan is primarily
converted into KYN leading to reduced availability of tryptophan for serotonin biosynthesis
and, consequently, altered serotonergic transmission in the brain with neuropsychiatric symp-
toms as a direct result of this cascade [10, 11]. However, as the brain may be able to compen-
sate for the inflammation-induced decrease in circulating tryptophan, the serotonergic system
may not be affected unfavorably as part of this process [11].
Recent research suggests that TRYCATs may exert effects independently of serotonin [11].
While KYN itself is inactive, it is further converted into different metabolites. KYN can be con-
verted into three different branches (see Fig 1).
1. Due the enzymatic activity of kynurenine-3-monooxygenase (KMO), KYN is converted
into 3-hydroxykynurenine (3-HK). Few enzymatic steps later in the cascade, 3-HK will be
finally converted into quinolinic acid (QUIN). Both exert neurotoxic properties due to
their ability to generate oxidative radicals and act as NMDA-receptor-agonists.
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2. Due the enzymatic activity of KYN aminotransferase II (KATII), KYN is converted into
kynurenic acid (KYNA), which as a NMDA-receptor-antagonist (like the antidementive
drug memantine) and α7-nicotinic acetylcholine receptor-antagonist tends to be neuropro-
tective [11, 12]. Kynurenic acid also acts neuroprotective against excitotoxicity of QUIN,
but an abnormal accumulation of KYNA beyond physiological levels could induce glutama-
tergic hypo-functioning and might disturb cognitive function [13]. High KYNA levels are
also discussed to be involved in the pathophysiology of cognitive and psychotic features of
schizophrenia [14].
3. KYN is a substrate for formation of anthranilic acid (AA), catalyzed by kynureninase
(KYNU). Levels of AA were reported to be elevated in schizophrenia and the autoimmune
diseases of rheumatoid arthritis and diabetes type 1 [15–17]. Less is reported about AA
from a hypothetically relevant functional perspective. It might prevent tryptophan deple-
tion, first by inhibiting sodium-transporters of uncharged solutes (e.g., tryptophan) across
membranes [18], and second by serving as a substrate for bacteria metabolism, e.g. in the
intestinal microbiome [19].
To date, studies on TRYCAT alterations in BD have only sporadically been conducted. Ele-
vated levels of KYN and KYNA have been described in the post mortem anterior cingulate in
BD patients with a history of psychosis [20]. CSF studies showed higher KYNA levels in 31
male BD patients compared to 23 male healthy controls (HC) [21], and notably being associ-
ated to manic and psychotic features [22, 23]. Johannson et al. [24] showed TRYCAT-alter-
ations in ten BD patients (two of them were euthymic) with increases of 3-HK and KYNA
synthesis in cultures of skin fibroblasts compared to twelve HC [24].
In the current investigation, we wanted to elucidate the peripheral measurements of KYN
metabolism in patients with BD. To our knowledge there is no study investigating blood levels
and ratios of key components of the KYN pathway in a large BD compared to a large HC sam-
ple. In clinical studies, evaluation of ratios between end-products and substrates are used for
the estimation of activities of enzymes [25].
We therefore analyzed the 3-HK/KYN as a proxy of the KMO, KYNA/KYN as a proxy of
KAT II and AA/KYN as a proxy of KYNU. We also evaluated the 3-HK/KYNA ratio, as this
ratio is often used in literature as a proxy of neurotoxic vs. neuroprotective end-product rela-
tion [26]. To complete the analysis we also wanted to present the serum levels of the pathway
(KYN, KYNA, 3-HK and AA) and see if they differ between BD and HC.
Fig 1. Kynurenine pathway. Enzymes are written in italic.
doi:10.1371/journal.pone.0172699.g001
Increased breakdown of KYN towards its neurotoxic branch in BD
PLOS ONE | DOI:10.1371/journal.pone.0172699 February 27, 2017 3 / 14
Our hypothesis was that euthymic BD show a bias to the more neurotoxic cascade of KYN
derivatives compared to HC. In particular this would imply a relative increase of the conver-
sion of KYN to the neurotoxic 3-HK in the BD sample, presuming an accelerated KMO activ-
ity and additionally we expected an increased 3-HK/KYNA ratio.
Methods
The study was conducted at the Medical University of Graz, Department of Psychiatry. All
patients took part in the ongoing single centre BIPFAT study, that assesses demographic
parameters, complete actual and lifetime psychiatric history using the Structured Clinical
Interview according to DSM-IV (SCID I), the psychiatric rating scales Hamilton-Depression
(HAM-D) [27], Young Mania Rating Scale (YMRS) [28] and Beck’s Depression Inventory
(BDI) [29], history of medication, anthropometric measure, blood pressure, fasting blood, cog-
nitive testing, EEG, stool sample, different lifestyle questionnaires and magnetic resonance
imaging (MRI) of the brain. All patients included were former in- or outpatients of the Medi-
cal University of Graz and had a diagnosis of BD I or BD II according to the DSM-IV criteria.
Patients needed to be in the state of euthymia or mild depression (HAM-D score <14 and
YMRS<9) and had given written informed consent prior to participating in the study.
The study has been approved by the local ethics committee (Medical University of Graz,
Austria) in compliance with the current revision of the Declaration of Helsinki, ICH guideline
for Good Clinical Practice and current regulations (EK-number: 24–123 ex 11/12).
Exclusion criteria were the presence of chronic obstructive pulmonary disease, rheumatoid
arthritis, systemic lupus erythematosus, inflammatory bowel disease, neurodegenerative and
neuroinflammatory disorders (i.e. Alzheimer’s, Huntington’s and Parkinson’s disorder, multi-
ple sclerosis), hemodialysis and interferon-α-based immunotherapy. Further exclusion criteria
for controls were the presence of lifetime psychiatric diagnoses (verified by SCID I) and first
and second grade relationship to relatives with psychiatric disorders. For further information
about the study design and preliminary results see our previous reports [2, 30–33].
We took peripheral TRYCAT blood levels of 143 euthymic and mild depressive BD patients
and 101 healthy controls. Targeted parameters were the levels of KYN, KYNA, 3-HK and AA,
the ratio between end-products and substrates as proxies for the specific enzymatic activity
(3-HK/KYN, KYNA/KYN, AA/KYN) as well as 3-HK/KYNA as a proxy for neurotoxic vs.
neuroprotective end-product relation. Because of technical issues AA could only be evaluated
in 113 BD and 88 HC.
For statistical analysis two multivariate analyses of covariance (MANCOVA) separated for
targeted parameters involving AA (113 BD and 88 HC)and not involving AA (BD:143 and
HC:101) controlled for age, sex, body mass index, presence of a cardiovascular disease and
smoking were performed, as the groups differed in these parameters (see Table 1).
We didn’t control for medication because every BD patient had at least one kind of psycho-
pharmacologic medication while HC didn’t. Thus it was simply not a feature applying to both
groups and not suitable as a factor to control for. Moreover to address this point we analyzed if
the targeted parameters differed in between patients with different kind of medications (lith-
ium, antipsychotics, antiepileptics and antidepressants), which was not the case (data not
shown).
Biological assays/Quantification of KYN pathway metabolites
(TRYCATs)
The chromatographic system was composed of a Waters Acquity UPLC separations module
connected to a Xevo TQ MS triple-quadrupole mass spectrometer, equipped with a Z-spray
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ESI ion source (Waters Corp., Milford, MA, USA). Separation was carried out using a Kinetex
XB-C18, 2.6 μm, 2.1 x 150 mm column (Phenomenex, Torrance, CA, USA).
Reagents for protein precipitation, derivatization, and chromatography were purchased
from Sigma-Aldrich (St. Louis, MO, USA) and Biosolve (Valkenswaard, NL).
KYN, AA, 3-HK and KYNA, were purchased from Sigma-Aldrich. The internal standard
KYNA-D5 was purchased from CDN Isotopes (Pointe-Claire, QC, Canada), KYN-D4 was
purchased from Buchem BV (Minden, NL). Standards and a low and high quality control were
established by adding defined amounts of each analyte to human serum samples (obtained
from a blood bank). The human serum was necessary to take matrix effects into account, in
order to cover concentrations below the analyte concentrations present in healthy humans the
serum was diluted 1+1 with LC-MS/MS grade water and used as the lowest calibrator. The val-
ues of this calibrator were calculated by standard addition. As serum without these analytes is
not available as there is no blank sample. A total volume of 300 μl serum samples, calibrators
and controls was used for sample preparation. Analytes were extracted by adding 50 μl of 2.0
M urea and 50 μl of an internal standard solution containing KYN-D4 and KYNA-D5. Two
precipitation steps by subsequently adding 200 μl methanol/ethanol (2/1 v:v) and 800 μl aceto-
nitrile were carried out. The supernatant was separated into two portions, which were evapo-
rated separately. One of these portions was directly reconstituted in mobile phase, while the
other portion was derivatised with 200 μl HCl/Butanol at 90˚C for 60 minutes. After evapora-
tion this portion was reconstituted in mobile phase as well.
For chromatography, 7.5 μl of the reconstituted samples, calibrators and controls were
loaded onto the LC-MS/MS system. The analytes were analysed in the underivatised sample.
Gradient methods with a total duration of 7.5 min each were used for chromatographic separa-
tion. Mobile phase A was composed of 0.1% formic acid and 0.01% HFBA in water, mobile
phase B was methanol. Flow rate was set at 0.25 ml/min, column temperature was set at
30.0˚C. Retention times for the analytes were between 3.1 and 6.0 min.
The Xevo TQ MS was operating in atmospheric pressure and electrospray ionization in
positive mode (ESI+). Ion source settings were: capillary voltage, 1.00 kV; desolvation temper-
ature 650˚C; source temperature, 150˚C; nitrogen was used as desolvation gas with an API gas
Table 1. Demographic and clinical parameters.
BD (n = 143) HC (n = 101) Statistics p
Male (%)* 55.9 39.6 χ 2 = 6.323 .012
Age (years) (M, SD)* 43.9 (13.3) 40.3 (16.4) U = -2.392 .017
Body Mass Index (M, SD)** 28.2 (6.2) 24.7 (4.3) U = -4.954 .000
Cardiovascular Disease (%)* 29.4 26.8 χ 2 = 5.035 .025
Smoking (%)** 48.3 26.7 χ 2 = 10.502 .001
Lithium (%) 32.2 0 n.a.
Antipsychotics (%) 62.2 0 n.a.
Antiepileptics (%) 32.2 0 n.a.
Two or more mood stabilizer (%) 33.6 0 n.a.
Antidepressant (%) 68.5 0 n.a.
Bipolar Disorder I (%) 61.5 n.a. n.a.
Bipolar Disorder II (%) 35.0 n.a. n.a.
Note: Results from Chi square tests (χ2) and Mann-Whitney-U-tests (U). Statistically significant effects are marked bold. (n.a. = not applicable)
*p <.05,
** <.01
doi:10.1371/journal.pone.0172699.t001
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flow rate of 1200 l/h; argon was used as collision gas at a flow rate of 0.15 ml/min. The analytes
and internal standards were detected using multi reaction monitoring (MRM) technique. Sys-
tem operation, data acquisition and data processing were controlled using MassLynx V4.1
software (Waters Corp.). The Lower Limit of Quantification and Lower Limit of Detection of
the used method were calculated according to DIN 32645 guidelines. The method was further
validated based on the EMEA guidelines at the Institute of Laboratory Medicine, Medical Cen-
ter of Ludwig Maximilian University, Munich, Germany.
Results
The levels of KYNA (F = 5,579; p<.05) were reduced in BD compared to HC (see Figs 2 and
3). There was no statistical difference in the other parameters.
The approximated enzymatic activity of the kynurenine-3-monooxygenase (KMO)
reflected by the 3-HK/KYN ratio was increased in BD individuals compared to HC (F = 5,394;
p<.05). Additionally the ratio of 3-HK/KYNA was increased in individuals with BD compared
to HC (F = 11,357; p<.01) (see Figs 4 and 5). There was no statistical difference in the other
investigated ratios.
Chromatograms of the investigated tryptophan pathway intermediates analyzed with high
pressure liquid chromatography coupled with mass spectrometry (HPLC-MS/MS) in Multiple
Reaction Monitoring (MRM) are shown in the supplementary S1 File.
Fig 2. Serum levels of TRYCATs in ng/mL. Results from MANCOVA controlled for age, sex, body mass index, presence of a cardiovascular
disease and smoking; *p<0.05; KYN = kynurenine, KYNA = kynurenic acid, 3-HK = 3-hydroxykynurenine, AA = anthranilic acid.
doi:10.1371/journal.pone.0172699.g002
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Fig 3. Scatter graphs showing the distribution of the serum levels of the measured TRYCATs in ng/mL.
doi:10.1371/journal.pone.0172699.g003
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Discussion
The aim of the present study was to elucidate the KYN pathway in euthymic individuals with
BD. We wanted to evaluate the serum levels of KYN, KYNA, 3-HK and AA as well as the
approximated activity of the KMO (measured by 3-HK/KYN ratio), KAT II (measured by
KYNA/KYN ratio), KYNU (measured by AA/KYN ratio) and the relation of the neurotoxic
TRYCAT 3-HK compared to the more neuroprotective TRYCAT KYNA (measured by 3-HK/
KYNA ratio) between euthymic individuals with BD and HC.
The results presented here give further supporting evidence for the contribution of TRY-
CATs, in particular KYN and its derivatives, to the pathophysiology of BD.
We could show a significant bias to the neurotoxic branch of KYN breakdown. The level of
KYNA was significantly decreased in individuals with BD, while the increase in 3-HK levels
compared to HCs didn’t reach statistical significance. There was a significant increase of 3-HK
compared to the more neuroprotective KYNA, evident by an increased 3-HK/KYNA ratio, as
well as an increased 3-HK/KYN ratio, as a proxy for KMO activity, in a sample of 143 euthy-
mic BD patients compared to 101 HC. There was no significant difference of the approximated
KAT II or KYNU activity between BD and HC.
TRYCATs are proposed to be mediators of immune-inflammatory activity and also neuro-
degeneration [7]. This increase of the neurotoxic catabolite 3-HK compared to the neuropro-
tective KYNA even in the state of euthymia might relate to cognitive dysfunction, which is
Fig 4. Ratios of TRYCAT metabolism. Results from MANCOVA controlled for age, sex, body mass index, presence of a cardiovascular disease
and smoking; *p<0.05, **p<0.01; KYN = kynurenine, KYNA = kynurenic acid, 3-HK = 3-hydroxykynurenine, AA = anthranilic acid.
doi:10.1371/journal.pone.0172699.g004
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Fig 5. Scatter graphs showing the distributions of the TRYCAT metabolism ratios.
doi:10.1371/journal.pone.0172699.g005
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prevalent in acute phases of BD, but also frequently prevails in euthymia [1, 2]. These processes
might also be partially responsible for unspecific brain structural changes in BD, like reduction
in grey and white matter, increased white matter lesions and microstructural changes which
can be found in various Magnetic resonance imaging (MRI)-studies [3–6]. Alterations in dif-
ferent immune-inflammatory processes are evident in BD. In particular its implications to the
KYN pathway have been highlighted by the study of Johansson et al. [24], which showed that
pro-inflammatory cytokine treatment (with human recombinants of interleukin-1, interleu-
kin-6, tumor-necrosis-factor and interferon-α (IFN-α) led to an IDO-1 activation and further
increase of the already elevated 3-HK/KYNA ratio, in cultures of skin fibroblasts, suggesting
that pro-inflammatory states are linked to an even greater imbalance. Raisson et al. [34]
showed a significant increase towards the KYN-pathway metabolism combined with associ-
ated increase of depressive symptoms in 27 hepatitis C following a IFN-α treatment. The IDO-
1 activity in general is enhanced by inflammatory pathways. We could show this in our previ-
ous preliminary results on increased IDO-1 activity in euthymic BD patients compared to HC
with greater increases noted in the subsample of overweight BD patients [30]. However, the
tryptophan breakdown in peripheral blood of individuals with BD has not been extensively
studied to date.
Accumulating evidence suggests that mild inflammatory processes in the periphery and the
brain are involved in the pathophysiology of BD across manic and depressive episodes but
may prevail throughout the euthymic “between-episode” period as a chronic process [35, 36].
The euthymia in BD is of special interest, as it is characterized by the absence of affective symp-
toms and the confounding of a state effect is removed. We also controlled for the potential
confounding factors obesity, smoking and cardiovascular disease, as they are all linked to low
grade inflammation [37–39] and were significantly more common in the investigated BD
group in our cohort, as expected due different earlier studies [40–42].
As a result of these foregoing observations it seems like we could at least hypothetically
think about crafting an approach to a possible biomarker (or at least a part of a combined bio-
marker with other parameters) for the recognition and staging of disease episodes in BD. As
manic and depressive episodes seem to be accompanied by increased inflammation [35, 36], a
measureable individual activation of the KYN-pathway could be detectable. To further eluci-
date that process a longitudinal assessment-approach across episodes in individuals with BD
seems like a good way to achieve that information.
Limitations
The mismatch of BD patients and healthy controls in important parameters, even if we con-
trolled for their influence, especially the difference in age is a limiting factor of the study. The
medication might also be of limiting contribution, as all BD individuals had psychopharmaco-
logical treatment, while no HC had these kinds of medications. To address this point we
analyzed if the targeted parameters differed in between patients with different kind of medica-
tions. Despite this was not the case in our sample, the influence of ongoing drug treatment
among patients can still not be ruled out. The study is also limited by its cross-sectional design.
The contribution of neurotoxic TRYCATs to cognitive decline and brain structural abnormali-
ties despite being logically sound is only hypothetical. Another limitation comes from the fact
that we took peripheral levels of the targeted parameters. This could be a problem for the inter-
pretation of KYNA levels and ratios as animal models teach us that KYNA diffuse only in very
low rate beyond the brain-blood barrier [43]. However, other authors propose that the same
processes involving KYN catabolism in the brain should basically also take place in the periph-
ery [8, 34]. The other TRYCATS (KYN, 3-HK and AA) are proposed to pass the brain-blood
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barrier easily [43, 44]. Nevertheless, as we are unable to precisely relate the peripheral measure-
ment of the investigated metabolites to the central nervous system in general and especially
not to the relevant brain regions or circuits, it seems far too speculative to say these markers
should be seen in a causative role for the disorder itself. In this context, we have to point out
that the investigated plasma metabolites should rather be seen as surrogate markers.
A further limitation is the use of the 3-HK/KYN ratio as a proxy of the KMO activity as it
may also reflect increased availability of precursor, i.e. kynurenine, especially in the view of
decreased conversion of KYN to KYNA. Considering the fact that the enzyme does not operate
under full saturation, bigger pool of KYN will be also be converted into 3-HK without notice-
able changes in free KYN levels.
Conclusion and future directions
In conclusion our findings subserve the concept of KYN-pathway alterations in the pathophys-
iology of BD. We present evidence of increased breakdown towards the neurotoxic branch in
KYN metabolism, which could be involved in the development of brain structural changes and
cognitive deficits in BD although direct extrapolation from observations made in serum to
brain cell metabolism remains elusive. Further research should focus on state dependent
changes in TRYCATs and its relation to cognition, brain structure and staging parameters
favorably in a longitudinal design across different episodes of disease. Moreover, the contribu-
tion of sex and metabolic parameters seems to be of special interest and should be further
analyzed.
Supporting information
S1 File. Chromatograms of tryptophan pathway intermediates. Chromatograms of the
investigated tryptophan pathway intermediates analyzed with high pressure liquid chromatog-
raphy coupled with mass spectrometry (HPLC-MS/MS) in Multiple Reaction Monitoring
(MRM).
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